BiotechTube

Binimetinib Oral Tablet

Phase 1UNKNOWN
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Melanoma

Conditions

Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma

Trial Timeline

Sep 3, 2021 → Nov 29, 2021

NCT ID
NCT05103891

About Binimetinib Oral Tablet

Binimetinib Oral Tablet is a phase 1 stage product being developed by Biotrial for Melanoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT05103891. Target conditions include Melanoma, BRAF V600 Mutation, Unresectable Melanoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05103891Phase 1UNKNOWN

Competing Products

20 competing products in Melanoma

See all competitors
ProductCompanyStageHype Score
Tasisulam-sodium + PaclitaxelEli LillyPhase 3
77
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT01 + [68Ga]VMT02Perspective TherapeuticsPhase 1
25
FYB206 + KeytrudaFormycon AGPhase 1
25
PLX3397Daiichi SankyoPre-clinical
23
PLX3397 + PembrolizumabDaiichi SankyoPhase 1/2
41
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
DS-8273a + NivolumabDaiichi SankyoPhase 1
33
PLX3397 + vemurafenibDaiichi SankyoPhase 1
33
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
52
CP-461Astellas PharmaPhase 2
52
YM155Astellas PharmaPhase 2
52
YM155 + DocetaxelAstellas PharmaPhase 2
52
Denileukin diftitoxEisaiPhase 2
52
E7080EisaiPhase 1
33
lenvatinib + pembrolizumabEisaiPhase 2
52
MORAb-004 (monoclonal antibody)EisaiPhase 2
52
Pembrolizumab + LenvatinibEisaiPhase 2
52
Lenvatinib + Lenvatinib + DacarbazineEisaiPhase 1/2
41
E7386 + Pembrolizumab + LenvatinibEisaiPhase 1/2
41

Other Products from Biotrial

EXS21546Phase 1/2
33
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)Phase 1/2
33
LPH-5 + PlaceboPhase 1
25
ITF2357Phase 1
25
VNA-318 + PlaceboPhase 1
25